Articles in the Category ”References”

SialEXO® 23 in a Study of Osteoclast Fusion

March 16, 2022 | References |

In a recent paper from Johns Hopkins University School of Medicine in Baltimore, removal of sialic acids from toll-like receptor 2 using SialEXO 23 was found to inhibit osteoclast fusion. These new findings in osteoclast recognition signaling are important for understanding the pathogenesis of different skeletal disorders, also showcasing the versatility of Genovis SmartEnzymes!
 
Read more »

FabRICATOR® in an Inline Electrochemical Reduction Workflow

February 17, 2022 | References |

An inline electrochemical reduction workflow for antibodies coupled with LC-MS analysis is described in this paper from the National Institute for Bioprocessing Research and Training in Dublin. The FabRICATOR enzyme (IdeS) is a key component in the subunit analysis by digesting antibodies at a single site below the hinge, generating a homogenous pool of F(ab’)2 and Fc subunits.
 
Read more »

SialEXO® in a Glycoform Analysis of Intact Erythropoietin

January 19, 2022 | References |

In this study, scientists at Leiden University Medical Center present a MALDI FT-ICR MS method for the glycosylation profiling of intact erythropoietin (EPO). The sialidase mix SialEXO significantly reduced the mass spectrum complexity and facilitated the interpretation of the complex spectra of intact EPO.
 
Read more »

GlycINATOR® in Peptide Mapping of Fc Domain-Drug Conjugates


The field of antibody-drug conjugates (ADCs) is rapidly emerging as a new, important class of cancer therapeutics. ADCs consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs, and after selective surface receptor binding on cancer cells, the drug is delivered into the intracellular compartment and can exert its cytotoxic effect.
 
Read more »

FabALACTICA® in a Quantitative IgG1 Clone Profiling

September 23, 2021 | Applications, References |

Our immune system protects us from pathogens and various diseases, and the immune response is dependent on a person’s repertoire of immune cells, antibodies and circulating plasma proteins. A detailed characterization of these plasma components is important for the understanding of how they affect each individual’s immune response.
Read more »

FabRICATOR® in a DAR Analysis of Antibody-Oligonucleotide Conjugates

September 16, 2021 | Applications, References |

In this paper, scientists at Spectroswiss and Orion Pharma present a novel strategy for DAR analysis of structurally complex antibody-oligonucleotide conjugates using SmartEnzymes™ and a proteoform integration approach combined with native SEC-Orbitrap FTMS.
 
Read more »

FabRICATOR in a Comprehensive Characterization of a Bispecific Antibody

September 9, 2021 | Applications, References |

Scientists at University of Geneva and Centre d’Immunologie Pierre-Fabre here describes a comprehensive intact and middle-level characterization of a commercial bispecific antibody by using a variety of orthogonal chromatographic methods coupled to MS.
 
Read more »

GingisREX® in a Bottom-Up Analysis of Histones


Bottom-up mass spectrometry where the intact protein is digested into smaller peptides is an indispensable tool for proteomics and the studying of histone codes. Since histones are enriched with the basic amino acids arginine and lysine, enzymatic digestion is often challenging as peptides too short for LC retention and PTM localization are generated. In addition, the complex workflow entails that the combination of samples preparation, data acquisition and analysis provides a different image of the histone code.

 

Read more »

Purification of Antibody Fragments via Hydrophobic Interactions


The importance of monoclonal antibodies (mAbs) as therapeutic agents is steadily increasing, and each year nearly 300 novel mAbs are being evaluated for their therapeutic effectivity. Interest has also been expressed in the use of antibody fragments as therapeutic agents. The physiochemical properties of the fragments differ significantly from that of intact antibodies, and the fragments can more easily be coupled to dyes, toxins and vesicles for diagnostic purposes, cancer therapy and improved drug delivery, respectively.
Read more »

Analytical Methods to Monitor Site-Specific ADC Generation with GlyCLICK®


Scientists at the University of Strasbourg and University of Geneva use innovative native MS and IM methodologies for analytical characterization of a site-specific ADC generated with the GlyCLICK technology.

 

Antibody-drug conjugates (ADCs) combine the benefits of tumor-targeting monoclonal antibodies with the cytotoxic effect of drug payloads covalently linked to the antibody. The ADC generation process has evolved from non-selective and uncontrolled conjugation in early generation products, to site-specific conjugation resulting in homogenous and well-defined ADCs. Conjugation at the antibody Fc glycan sites using the GlyCLICK technology has proven to be an attractive option for the generation of site-specific ADCs.
Read more »